Zhongfeng Liu - Publications

Enhanced anti-tumor activity mediated by combination chimeric antigen receptor T cells targeting GD2 and GPC2 in high-risk neuroblastoma.

Journal: Cytotherapy

Published: January 26, 2024

Therapeutic effects against high-grade glioblastoma mediated by engineered induced neural stem cells combined with GD2-specific CAR-NK.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: June 28, 2023

A CH2CH3 hinge region enhances the cytotoxicity of anti-CD5 CAR-T cells targeting T cell acute lymphoblastic leukemia.

Journal: International immunopharmacology

Published: June 25, 2023

In vitro differentiation of human CD45+ CD34+ induced hematopoietic progenitor cells from iPSCs using a monolayer system.

Journal: Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis

Published: April 18, 2023

GD2 CAR-T cells in combination with Nivolumab exhibit enhanced antitumor efficacy.

Journal: Translational oncology

Published: January 20, 2023

Long-Term Safety and Efficacy of CD19 Humanized Selective CAR-T Therapy in B-ALL Patients Who Have Previously Received Murine-Based CD19 CAR-T Therapy.

Journal: Frontiers in oncology

Published: February 27, 2022

Case Report: Humanized Selective CD19CAR-T Treatment Induces MRD-Negative Remission in a Pediatric B-ALL Patient With Primary Resistance to Murine-Based CD19CAR-T Therapy.

Journal: Frontiers in immunology

Published: July 07, 2020

Treatment with Humanized Selective CD19CAR-T Cells Shows Efficacy in Highly Treated B-ALL Patients Who Have Relapsed after Receiving Murine-Based CD19CAR-T Therapies.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 21, 2019